The Spleen Polypeptide Injection On T Lymphocyte Subsets In Severe Burn Patients

Background: After burn the body will appear different degrees of immune dysfunction has been confirmed that a large number of clinical and experimental data. Burn patients after immune dysfunction is cause the body to infection, MODS,SIRS, and even the important cause of death. How to correct the immune disorder patients, improve the body’s ability to fight bacterial pathogens, reduce the complications and improve the cure rate has always been a concern in clinical workers. With the development of molecular biology, pharmaceutical engineering technology improvement, people developed a variety of immune regulator used in clinical treatment. Spleen polypeptide injection in recent years, as a new type of immunomodulatory drugs are widely used in malignant tumor, the respiratory tract and lung infection, primary and secondary cell immune deficiency disease, etc., has obtained the good curative effect, but the spleen polypeptide injection in burn the specific efficacy are rarely reported.Objective: Discusses the spleen polypeptide injection on T lymphocyte subsets in severe burn patients. For clinical treatment of severe burn when it provides the theory basis for how to improve the body’s immune function, which helps to reduce the incidence of infection and multiple organ failure, reduce complications and improve cure rate. Shorten the length of hospital stay, reduce patient pain.Methods: Selected in March 2013 to November 2013 in Department of Burns Plastic surgery of Yan’an university Affiliated Hospital of 52 cases of severe burn patients admitted in 2013,(including 2 cases give up treatment, 1 case of adverse reaction, has been dropped) severe burn patients, the patients’ informed consent is divided into two groups. Treatment group on the second day after admission, spleen polypeptide injection treatment, add 10 ml to 500 ml of 0.9% sodium chloride injection of spleen polypeptideinjection, intravenous drip, daily 1 time, period of treatment 14 d; Control group do not give spleen polypeptide injection treatment, the rest of the regular treatment(including rehydration, anti-infection, symptomatic support treatment and wound treatment, etc.) in the two groups are the same. Respectively before and after treatment days 7, 14, 2 l extraction in patients with peripheral venous blood, using flow cytometry to test two groups of patients with total number of T lymphocytes(CD3+) and T lymphocyte subsets(CD4+, CD8+, CD4+/CD8+) as the observation indexes; 7, 14, 21 days after the treatment respectively on two groups of patients with blood bacteria culture and wound secretion bacteria culture, record the number of positive; Observe and record in the course of the disease complicated by infection, the number of related system.Results: 1. Two groups of patients with peripheral venous blood T lymphocyte subgroup comparison: Two groups of patients before treatment and after treatment for 7 days, 14, 21 days of peripheral blood T lymphocytes(CD3+), total differences had no statistical significance(P > 0.05). Two groups of patients before treatment number of CD4+ cells, there was no statistically significant difference(P > 0.05); 7 days after treatment, 14 days, 21 days of the two groups of patients with CD4+ cell count, the difference had statistical significance(P < 0.05), treatment group CD4+ cell count is higher than the control group. Two groups of patients before treatment and after treatment 7 days CD8+ cells count, there were no statistically significant difference(P > 0.05); 14 days after treatment, two groups of patients with 21 days of CD8+ cells number comparison, the difference had statistical significance(P < 0.05), and CD8+ treatment group is lower than in the control group. Two groups of patients before treatment of CD4+/CD8+ ratio comparison, there was no statistically significant difference(P > 0.05); 7 days after treatment, 14 days, 21 days of CD4+/CD8+ ratio comparison, the difference had statistical significance(P < 0.05), the treatment group the CD4+/CD8+ ratio is higher than the control group. 2. Related infections in patients with two groups of comparison:On admission, the performance of the two groups of patients have no related infections; The whole research process, the two groups of patients with blood cultures were negative, no respiratory infections. 14 and 21 days after treatment, the wound germiculture positive was significantly lower in treatment group than the control group, two groups of patients in the treatment of wounds germiculture positive rate respectively is: 14 days after treatment group: 8%, control group: 20.8%; 21 days after the treatment of wounds, germiculture positive rate respectively is: the treatment group: 0%, control group: 8.3%; The whole research process, the treatment group patients with indwelling catheter in 12 cases, control group patients with indwelling catheter in 11 cases, 14 days after treatment, two groups of the patients with indwelling catheter, a urinary tract infection were 0% and 18.2% respectively.Conclusion: Spleen polypeptide injection as an immune regulator, has a regulatory role in the body’s immune function, caused by the body of severe burn were able to correct the T lymphocyte subgroup imbalances, enhance lymphocyte immune function, enhance the body’s ability to fight infection, so as to help reduce severe infection, multiple organ dysfunction syndrome, the incidence of systemic inflammatory response syndrome, improve the cure rate.